Mechanisms Underlying Coagulation Abnormalities in Ebola Hemorrhagic Fever: Overexpression of Tissue Factor in Primate Monocytes/Macrophages Is a Key Event

Journal of Infectious Diseases

Volumn 188, Issue 11, 2003, Pages 1618-1629

  Geisbert, Thomas W ^a,e   Young, Howard A ^c   Jahrling, Peter B ^b   Davis, Kelly J ^b   Kagan, Elliott ^d   Hensley, Lisa E ^a  

^a Dept of Immunol and Molec Biology Bldg 1425 U States Army Med R   (United States)

^b Headquarters   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C; RNA; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA VIRUS; FIBRINOLYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MACACA; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; VIRUS HEMORRHAGIC FEVER;

ANIMALS; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRIN; HEMORRHAGIC FEVER, EBOLA; MACACA FASCICULARIS; MACACA MULATTA; MACROPHAGES; MALE; MONOCYTES; RNA, MESSENGER; THROMBOPLASTIN;

EID: 0348053693     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379724     Document Type: Article

References (51)

1. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, Peters CJ. Filoviridae. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott, Williams, & Wilkins, 2001:1279-304.
2. Fisher-Hoch SP, Brammer LT, Trappier SG, et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 1992; 166:753-63.
3. Jaax NK, Davis KJ, Geisbert TW, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120:140-55.
4. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7.
5. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999; 82:695-705.
6. Mammen EF. Disseminated intravascular coagulation (DIC). Clin Lab Sci 2000; 13:239-45.
7. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001; 16:167-77.
8. Gando S, Nanzaki S, Kemmotsu O. Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. Ann Surg 1999; 229:121-7.
9. Levi M, de Jonge E, van der Poll T, ten Gate H. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thromb Hemost 2001; 27:569-75.
10. Wilson RF, Mammen EF, Tyburski JG, Warsow KM, Kubinec SM. Antithrombin levels related to infections and outcome. J Trauma 1996; 40: 384-7.
11. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33:127-34.
12. Arai A, Hirano H, Ueta Y, Hamada T, Mita T, Shirahata A. Detection of mononuclear cells as the source of the increased tissue factor mRNA in the liver from lipopolysaccharide-treated rats. Thromb Res 2000; 97:153-62.
13. Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142:1458-70.
14. Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27:605-17.
15. Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144:273-83.
16. Hara S, Asada Y, Hatakeyama K, et al. Expression of tissue factor and tissue factor pathway inhibitor in rat lungs with lipopolysaccharide-induced disseminated intravascular coagulation. Lab Invest 1997; 77: 581-9.
17. Gedigk P, Bechtelsheimer H, Korb G. Die pathologische anatomie der Marburg-virus-Krankheit. Dtsch Med Wochenschr 1968; 93:590-601.
18. Murphy FA. Pathology of Ebola virus infection. In: Pattyn SR, ed. Ebola virus haemorrhagic fever. New York: Elsevier/North-Holland Biomedical Press, 1978:43-60.
19. Geisbert TW, Jaax NK. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct Pathol 1998; 22:3-17.
20. Egbring R, Slenczka W, Baltzer G. Clinical manifestations and mechanism of the hemorrhagic diathesis in Marburg virus disease. In: Martini GA, Siegert R, eds. Marburg virus disease. New York: Springer-Verlag, 1971:41-9.
21. Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. BMJ 1975; 4:489-93.
22. Isaacson M, Sureau P, Courteille G, Pattyn SR. Clinical aspects of Ebola virus disease at the Ngaliema Hospital, Kinshasa, Zaire, 1976. In: Pattyn SR, ed. Ebola virus haemorrhagic fever. New York: Elsevier/North-Holland Biomedical Press, 1978:15-20.
23. World Health Organization. Ebola haemorrhagic fever in Zaire, 1976: report of an international commission. Bull World Health Organ 1978; 56: 271-93.
24. Fisher-Hoch SP, Platt GS, Neild GH, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985; 152:887-94.
25. Geisbert TW, Jahrling PB, Hanes MA, Zack PM. Association of Ebola related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 1992; 106:137-52.
26. Davis KJ, Anderson AO, Geisbert TW, et al. Pathology of experimental Ebola virus infection in African green monkeys. Arch Pathol Lab Med 1997; 121:805-19.
27. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125: 243-53.
28. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(Suppl 1):S224-34.
29. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80:169-79.
30. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002; 8:119-26.
31. Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res 1995; 39:129-50.
32. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161:4382-7.
33. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95:930-5.
34. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor - dependent procoagulant activity. Blood 2002; 99: 3962-70.
35. Wills BA, Oragui EE, Stephens AC, et al. Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnamese children with dengue shock syndrome. Clin Infect Dis 2002; 35:277-85.
36. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96:2311-5.
37. Neumann F-J, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17:3399-405.
38. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85:967-72.
39. Bokarewa MI, Morissey JH, Tarkowski A. Tissue factor as a proinflammatory agent. Arthritis Res 2002; 4:190-5.
40. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477:349-60.
41. Yan SB, Grinnell BW. Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway. Ann Rep Med Chem 1994; 11:103-12.
42. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272:L197-202.
43. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29:S48-52.
44. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816-23.
45. Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-42.
46. Kidokoro A, Iba T, Fukunaga M, Yagi Y. Alterations in coagulation and fibrinolysis during sepsis. Shock 1996; 5:223-8.
47. Fisher CJ, Yan B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28:S49-56.
48. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79:918-25.
49. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
50. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179(Suppl 1):S199-202.
51. Huggins JW, Zhang ZX, Davis K, Coulombe RA. Inhibition of Ebola virus by S-adenosylhomocysteine hydrolase inhibitors. Antiviral Res 1995; 26:A301.